Evidence map›Paper›PMID 38687678›Full record

ArticleeLife2024

Loss of tumor suppressor TMEM127 drives RET-mediated transformation through disrupted membrane dynamics.

Timothy J Walker, Eduardo Reyes-Alvarez, Brandy D Hyndman, Michael G Sugiyama, Larissa C B Oliveira, Aisha N Rekab, Mathieu J F Crupi, Rebecca Cabral-Dias, Qianjin Guo, Patricia L M Dahia and 3 more

Open access · goldAbstract read
In one paragraph

Article in eLife, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 1 institution in 4 countries.

Timothy J WalkerDivision of Cancer Biology and Genetics, Cancer Research Institute, and Department of Pathology and Molecular Medicine, Queen's University, Kingston, Canada.ORCID https://orcid.org/0000-0002-6146-3485
Eduardo Reyes-AlvarezDivision of Cancer Biology and Genetics, Cancer Research Institute, and Department of Pathology and Molecular Medicine, Queen's University, Kingston, Canada.
Brandy D HyndmanDivision of Cancer Biology and Genetics, Cancer Research Institute, and Department of Pathology and Molecular Medicine, Queen's University, Kingston, Canada.ORCID https://orcid.org/0000-0003-4096-0922
Michael G SugiyamaDepartment of Chemistry and Biology, Toronto Metropolitan University, Toronto, Canada.
Larissa C B OliveiraDivision of Cancer Biology and Genetics, Cancer Research Institute, and Department of Pathology and Molecular Medicine, Queen's University, Kingston, Canada.ORCID https://orcid.org/0000-0001-6798-0662
Aisha N RekabDivision of Cancer Biology and Genetics, Cancer Research Institute, and Department of Pathology and Molecular Medicine, Queen's University, Kingston, Canada.
Mathieu J F CrupiDivision of Cancer Biology and Genetics, Cancer Research Institute, and Department of Pathology and Molecular Medicine, Queen's University, Kingston, Canada.
Rebecca Cabral-DiasDepartment of Chemistry and Biology, Toronto Metropolitan University, Toronto, Canada.
Qianjin GuoDivision of Hematology and Medical Oncology, University of Texas Health Science Center, San Antonio, United States.
Patricia L M DahiaDivision of Hematology and Medical Oncology, University of Texas Health Science Center, San Antonio, United States.ORCID https://orcid.org/0000-0002-7757-370X
Douglas S RichardsonDepartment of Molecular and Cellular Biology, Harvard Center for Biological Imaging, Scientific Image Analysis Group, Harvard University, Cambridge, United States.ORCID https://orcid.org/0000-0002-3189-2190
Costin N AntonescuDepartment of Chemistry and Biology, Toronto Metropolitan University, Toronto, Canada.ORCID https://orcid.org/0000-0001-9192-6340
Lois M MulliganDivision of Cancer Biology and Genetics, Cancer Research Institute, and Department of Pathology and Molecular Medicine, Queen's University, Kingston, Canada.ORCID https://orcid.org/0000-0002-9308-8245
Harvard University · US

Funding

Evaluating the impact of genetic ancestry on the biology and drug response profile of pheochromocytoma and paraganglioma-derived organoid modelsR01CA264248 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI DAHIA, PATRICIA LEAL, SORAGNI, ALICE · 2021 to 2025
$3.2M
Interaction of the TMEM127 tumor suppressor with the mTORC1 lysosomal activating complexR01GM114102 · NIGMS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI DAHIA, PATRICIA LEAL · 2017 to 2021
$1.5M
CIHR MOP-142303CIHR PJT-156355CIHR PJT-178274NCI NIH HHS R01 CA264248NIGMS NIH HHS R01 GM114102NIH HHS CA264248NIH HHS GM114102
6 · The paper itself

Abstract

Internalization from the cell membrane and endosomal trafficking of receptor tyrosine kinases (RTKs) are important regulators of signaling in normal cells that can frequently be disrupted in cancer. The adrenal tumor pheochromocytoma (PCC) can be caused by activating mutations of the rearranged during transfection (RET) receptor tyrosine kinase, or inactivation of TMEM127, a transmembrane tumor suppressor implicated in trafficking of endosomal cargos. However, the role of aberrant receptor trafficking in PCC is not well understood. Here, we show that loss of TMEM127 causes wildtype RET protein accumulation on the cell surface, where increased receptor density facilitates constitutive ligand-independent activity and downstream signaling, driving cell proliferation. Loss of TMEM127 altered normal cell membrane organization and recruitment and stabilization of membrane protein complexes, impaired assembly, and maturation of clathrin-coated pits, and reduced internalization and degradation of cell surface RET. In addition to RTKs, TMEM127 depletion also promoted surface accumulation of several other transmembrane proteins, suggesting it may cause global defects in surface protein activity and function. Together, our data identify TMEM127 as an important determinant of membrane organization including membrane protein diffusability and protein complex assembly and provide a novel paradigm for oncogenesis in PCC where altered membrane dynamics promotes cell surface accumulation and constitutive activity of growth factor receptors to drive aberrant signaling and promote transformation.

Indexed as

Cell MembraneMembrane ProteinsProto-Oncogene Proteins c-retAdrenal Gland NeoplasmsCell ProliferationCell Transformation, NeoplasticHumansProtein TransportSignal TransductionMembrane ProteinsProto-Oncogene Proteins c-retRET protein, humanTMEM127 protein, humancancer biologycell biologyclathrin-mediated endocytosishumanmembrane dynamicspheochromocytomaRETTMEM127

Identifiers

PMID38687678
PMCPMC11060712
OpenAlexW4386864644

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.